Table 2.
Meta-analysis of association between rs25487 or rs1799782 and efficacy of NSCLC treated with platinum-based chemotherapy in Asians.
| XRCC1 | ORR | OS | PFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | I 2 (%) | OR (95% CI) | p | No. | I 2 (%) | HR (95% CI) | p | No. | I 2 (%) | HR (95% CI) | p | |
| rs25487 (Arg399Gln)$ | ||||||||||||
| Homozygous model | 17 | 56.8 | 1.71 (1.16-2.52) | .007 | 12 | 63.2 | 0.60 (0.40-0.88) | .009 | 4 | 24.4 | 0.64 (0.46-0.90) | .010 |
| Heterozygous model | 17 | 29.0 | 1.23 (1.07-1.40) | .003 | 12 | 63.2 | 0.81 (0.64-1.03) | .083 | 4 | 0 | 0.87 (0.71-1.07) | .193 |
| Dominant model | 20 | 69.3 | 1.11 (0.87-1.41) | .386 | 5 | 39.4 | 1.00 (0.79-1.27) | .980 | 4 | 0 | 0.87 (0.71-1.08) | .215 |
| Recessive model | 18 | 54.2 | 1.45 (1.02-2.06) | .037 | 3 | 13.8 | 1.14 (0.82-1.59) | .490 | — | — | — | — |
| rs1799782 (Arg194Trp)# | ||||||||||||
| Homozygous model | 9 | 34.0 | 1.73 (1.31-2.27) | <.001 | 10 | 53.4 | 0.63 (0.43-0.91) | .013 | 4 | 0 | 0.93 (0.68-1.26) | .627 |
| Heterozygous model | 9 | 0 | 1.28 (1.06-1.55) | .007 | 10 | 0 | 0.89 (0.70-1.05) | .173 | 4 | 0 | 1.02 (0.83-1.26) | .838 |
| Dominant model | 9 | 25.5 | 1.38 (1.16-1.65) | <.001 | 4 | 0 | 0.91 (0.71-1.16) | .446 | 3 | 0 | 1.05 (0.83-1.34) | .662 |
| Recessive model | 9 | 12.5 | 1.56 (1.20-2.03) | <.001 | — | — | — | — | — | — | — | — |
$Homozygous, heterozygous, dominant, and recessive models indicated GlnGln vs. ArgArg, GlnArg vs. ArgArg, GlnGln+GlnArg vs. ArgArg ,and GlnGln vs. GlnArg+ArgArg, respectively. #Homozygous, heterozygous, dominant, and recessive models indicated TrpTrp vs. ArgArg, TrpArg vs. ArgArg, TrpTrp+TrpArg vs. ArgArg, and TrpTrp vs. TrpArg+ArgArg, respectively. Abbreviations: NSCLC: non-small-cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; OR: odds ratio; HR: hazard ratio.